Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials

The Lancet
Mar 05, 2022 Volume 399 Number 10328 p885-1022, e11
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
Lorcan P McGarvey, et al COUGH-1 and COUGH-2 Investigators